DE69629108D1 - Anwendung von ketamin zur entgiftung - Google Patents

Anwendung von ketamin zur entgiftung

Info

Publication number
DE69629108D1
DE69629108D1 DE69629108T DE69629108T DE69629108D1 DE 69629108 D1 DE69629108 D1 DE 69629108D1 DE 69629108 T DE69629108 T DE 69629108T DE 69629108 T DE69629108 T DE 69629108T DE 69629108 D1 DE69629108 D1 DE 69629108D1
Authority
DE
Germany
Prior art keywords
ketamine
present
substance addiction
administration
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69629108T
Other languages
English (en)
Other versions
DE69629108T2 (de
Inventor
Stuart L Weg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1995/002418 external-priority patent/WO1995022965A2/en
Priority claimed from US08/477,365 external-priority patent/US5679714A/en
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69629108D1 publication Critical patent/DE69629108D1/de
Publication of DE69629108T2 publication Critical patent/DE69629108T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69629108T 1995-02-24 1996-02-14 Anwendung von ketamin zur entgiftung Expired - Lifetime DE69629108T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US1995/002418 WO1995022965A2 (en) 1994-02-25 1995-02-24 Nasal and ocular administration of ketamine to manage pain and for detoxification
WOPCT/US95/02418 1995-02-24
US08/477,365 US5679714A (en) 1995-06-07 1995-06-07 Administration of ketamine for detoxification and treatment of tobacco addiction
US477365 1995-06-07
PCT/US1996/002047 WO1996025925A1 (en) 1995-02-24 1996-02-14 Nasal and ocular administration of ketamine to manage pain and for detoxification

Publications (2)

Publication Number Publication Date
DE69629108D1 true DE69629108D1 (de) 2003-08-21
DE69629108T2 DE69629108T2 (de) 2004-04-22

Family

ID=26789531

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69629108T Expired - Lifetime DE69629108T2 (de) 1995-02-24 1996-02-14 Anwendung von ketamin zur entgiftung

Country Status (9)

Country Link
EP (1) EP0814790B1 (de)
JP (1) JP4173538B2 (de)
AT (1) ATE245024T1 (de)
AU (1) AU733284B2 (de)
CA (1) CA2213567C (de)
DE (1) DE69629108T2 (de)
DK (1) DK0814790T3 (de)
ES (1) ES2205018T3 (de)
WO (1) WO1996025925A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111643449A (zh) 2013-03-15 2020-09-11 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
EP3725307A1 (de) 2014-09-15 2020-10-21 Janssen Pharmaceutica NV Val66met (snp rs6265)-genotypspezifische dosierschemata und verfahren zur behandlung von depression
US10555952B2 (en) 2015-06-19 2020-02-11 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10166240B2 (en) 2015-06-19 2019-01-01 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10179136B2 (en) 2015-06-19 2019-01-15 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10391102B2 (en) 2015-06-19 2019-08-27 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US9918993B2 (en) * 2015-06-19 2018-03-20 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for anesthesiological applications
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
SG11202005896WA (en) 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
ES2907692T3 (es) * 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
MX2021010683A (es) 2019-03-05 2021-12-10 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
CN116942648A (zh) * 2022-04-26 2023-10-27 宜昌人福药业有限责任公司 艾司氯胺酮液体制剂及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain

Also Published As

Publication number Publication date
WO1996025925A1 (en) 1996-08-29
DE69629108T2 (de) 2004-04-22
AU733284B2 (en) 2001-05-10
CA2213567C (en) 2010-01-26
EP0814790A1 (de) 1998-01-07
DK0814790T3 (da) 2003-11-10
ATE245024T1 (de) 2003-08-15
AU4982796A (en) 1996-09-11
ES2205018T3 (es) 2004-05-01
CA2213567A1 (en) 1996-08-29
JP4173538B2 (ja) 2008-10-29
JPH11500729A (ja) 1999-01-19
EP0814790B1 (de) 2003-07-16

Similar Documents

Publication Publication Date Title
MX9603633A (es) Administracion nasal y ocular de ketamina para manejar el dolor y para la detoxificacion.
DE69629108D1 (de) Anwendung von ketamin zur entgiftung
NO963322L (no) Fremgangsmåte for behandling av abstinens ved stoffmisbruk
NO20060913L (no) Behandling av avhengighetsabstinens
ATE184484T1 (de) Wirkstoffe zur behandlung von suchterkrankungen
ATE301462T1 (de) Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden
MX9706456A (es) Administracion nasal y ocular de la cetamina para manejar el dolor y para la destoxificacion.
EP1056458A4 (de) Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen
NO943293L (no) Anvendelse av et medikament ved avvenning mot röyk
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
Richmond et al. Controlled Trial of the 24-Hour Transdermal Nicotine Patch in Conjunction With Cognitive-Behavioural Therapy: 6-Months’ Results
JP2004505053A (ja) 喫煙の減少または解消方法
SU1537259A1 (ru) Средство, подавл ющее влечение к никотину и табачному дыму
RU2266116C1 (ru) Способ лечения табачной зависимости
Hendrie Alternative strategies and new treatments for smoking
Strain there is insufficient evidence for naltrexone maintenance treatment in opioid dependence
UA42352A (uk) Спосіб лікування хронічного гастродуоденіту із супутніми захворюваннями внутрішніх органів
UA18878A (uk) Спосіб лікуваhhя алкогольhої та hаркотичhої залежhості
JPS59155318A (ja) 細胞の活性剤とその活用方法

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336